> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Paxlovid Widely Available in Pharmacies: Farley
- URL: https://www.fdaweb.com/paxlovid-widely-available-in-pharmacies-farley/
- Published: 2022-05-04T12:00:00.000Z
- Updated: 2026-09-14T17:43:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151740

Pfizer’s Covid-19 treatment Paxlovid (nirmatrelvir tablets and ritonavir tablets) is now widely available in community pharmacies and is authorized for treating mild-to-moderate Covid-19 in adults and pediatric patients age 12 and older with positive results of direct SARS-CoV-2 viral testing who are also at high risk for progression to severe Covid-19, including hospitalization or death. In a *CDER Conversation*, Office of Infectious Diseases director **John Farley** [answers](https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers?ref=fdaweb.com) these questions about Paxlovid for healthcare providers: 

- what does “direct SARS-CoV- viral testing” mean and do patients need a positive PCR test to be treated with Paxlovid;
- how should healthcare providers assess a patient for ‘high risk for progression to severe Covid-19”;
- are there tools to help healthcare providers manage potential drug-drug interactions;
- is dose adjustment of Paxlovid needed for patients with moderate renal impairment;
- how can a community pharmacy that has Paxlovid in stock be located; and
- what is known about case reports of patients developing symptoms after completing a course of Paxlovid.